Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.

@article{Bertheau2002EffectOM,
  title={Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.},
  author={Philippe Bertheau and François Plassa and Marc Espie and Elisabeth Turpin and Anne de Roquancourt and Michel M. Marty and Florence Lerebours and Yves Beuzard and Anne Janin and Hugues de Th{\'e}},
  journal={Lancet},
  year={2002},
  volume={360 9336},
  pages={852-4}
}
TP53 activation by genotoxic drugs can induce apoptosis or cell-cycle arrest. Thus, whether the gene is mutated or wild type could affect the response of a tumour to chemotherapy. Clinical data are unclear, possibly as a result of heterogeneity of tumours, drugs, methods of assessing response, or TP53 status. We studied 50 non-inflammatory, locally advanced breast cancers that had been treated with high doses of a combination of epirubicin and cyclophosphamide. We noted eight complete responses… CONTINUE READING